Protocols
ADP-0000-001-SCR Phase N/A OPEN TO ACCRUAL
A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects with Solid or Hematological Malignancies
ALLIANCE-A151804 Phase N/A OPEN TO ACCRUAL
Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
ALLIANCE-A222004-ANOREXIA Phase III OPEN TO ACCRUAL
A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer-Associated Anorexia
ALLOVIR-AVM-003-HC Phase III OPEN TO ACCRUAL *
A Phase 3 Multicenter, Double-Blind, Placebo-Controlled Trial of Viralym-M (ALVR105) for the Treatment of Patients with Virus-Associated Hemorrhagic Cystitis after Allogeneic Hematopoietic Cell Transplant
ALLOVIR-P-106-001-RESP Phase I/II OPEN TO ACCRUAL *
Phase 1-2, double-Blind, Placebo-controlled, Dose Escalation and Expansion Study of ALVR106 in Addition to standard of Care for the Treatment of High-Risk patients with Respiratory Viral Infections After Hematopoietic Cell Transplant
CTN-1705 Phase III OPEN TO ACCRUAL
A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase III Trial of Alpha 1- Antitrypsin (AAT) Combined with Corticosteroids vs. Corticosteroids Alone for the Treatment of High-Risk Acute Graft-versus-Host-Disease (GVHD) Following Hematopoietic Stem Cell Transplant
IIT-RUNAAS-TILDRAKIZUMAB-AGVHD Phase II OPEN TO ACCRUAL
A Phase II Trial of Tildrakizumab for Prevention of Acute Graft-Versus-Host Disease
INCYTE-INCB-39110-211-CRS Phase II OPEN TO ACCRUAL
A Phase II, Single-Arm, Open-label Study of Itacitinib, for the Prevention of Cytokine Release Syndrome (CRS) Induced by Immune Effector Cell Therapy
SYNDAX-SNDX-6352-0504-CGVHD Phase II OPEN TO ACCRUAL
AGAVE-201, A Phase 2, open-label, Randomized, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of Axatilimab at 3 Different Doses in Patient with Recurrent or Refractory Active Chronic Graft Versus Host Disease Who Have Received at Least 2 Lines of Systemic Therapy